Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
Celebrating one year of Europe’s first Ustekinumab Biosimilar – supplied by STADA!
Chronic inflammatory diseases (CID) can progress silently, with symptoms like fatigue, joint pain, or skin changes often overlooked. For many patients, diagnosis comes late, when tissue damage has already occurred.
At STADA, improving access to effective treatment options for CID is essential. This anniversary marks another important moment in our continuous journey to broaden treatment options for patients with Chronic Inflammatory Diseases, while supporting healthcare systems across Europe.
Amel Belhani, Senior Commercial Manager Global Specialty at STADA, concludes: “This milestone highlights our commitment to making high-quality, affordable biologics accessible to more people and staying true to our purpose of Caring for People’s Health as a Trusted Partner.”
Why Biosimilars Matter
Biologics have transformed CID treatment by targeting specific pathways in the immune system. However, access is often limited due to high therapy costs and reimbursement challenges in some healthcare settings. Biosimilars help close this gap by offering equivalent quality, safety, and efficacy to reference biologics while improving affordability and expanding availability across multiple countries.
One year after our launch, we are proud to see the impact across Europe: more treatment options for patients, broader access in clinical practice, and closer collaboration with healthcare professionals to improve patient outcomes through early and effective treatment interventions.